Market Overview

Tandem Diabetes Care Positioned For 20-30% Growth, But Valuation Warrants Neutral Stance

Share:
Tandem Diabetes Care Positioned For 20-30% Growth, But Valuation Warrants Neutral Stance
Related
33 Stocks Moving In Wednesday's Pre-Market Session
The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Medical device maker Tandem Diabetes Care Inc (NASDAQ: TNDM) has high growth potential, but its upside could be limited by valuation, according to Bank of America Merrill Lynch.

The Analyst

Analyst Travis Steed upgraded Tandem Diabetes from Underperform to Neutral and hiked the price target from $2 to $45.

The Thesis

Tandem Diabetes' balance sheet is no longer a major concern, and there are "multiple levers to drive 20-30-percent growth for several years," Steed said in a Friday note. (See the analyst's track record here.) 

The company has a superior product in its insulin pump, with renewals contributing to upside, the analyst said.

Steed sees an incremental opportunity in the company's expansion into international markets. 

When the company's Control-IQ products become commercially available in 2019, the analyst said Tandem may even have an opportunity to disrupt Medtronic PLC (NYSE: MDT)'s exclusive deal with UnitedHealth Group Inc (NYSE: UNH).

Yet BofA noted that the shares are already trading at 11 times its 2019 revenue estimate, keeping the firm on the sidelines. 

BofA forecast 2018 sales of $146 million and 42-percent year-over-year growth, with the potential for $15 million in upside.

The Price Action

Tandem Diabetes shares have appreciated over 1,500 percent year-to-date.

The stock was losing 1.53 percent to $38.02 at the time of publication late in Friday's session. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict

Photo courtesy of Tandem Diabetes Care. 

Latest Ratings for TNDM

DateFirmActionFromTo
Sep 2018Craig-HallumInitiates Coverage OnBuy
Sep 2018BairdDowngradesOutperformNeutral
Aug 2018BerenbergInitiates Coverage OnBuy

View More Analyst Ratings for TNDM
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill Lynch Travis SteedAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (MDT + TNDM)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
AMTDMorgan StanleyUpgrades65.0
APOMorgan StanleyDowngrades34.0
ARMKBairdUpgrades44.0
CGMorgan StanleyDowngrades23.0
EIXEdward JonesDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

Bank of America Downgrades Acacia On Valuation, Competition